https://scholars.lib.ntu.edu.tw/handle/123456789/635379
標題: | MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia | 作者: | Mesa, Ruben Komatsu, Norio Gill, Harinder Jin, Jie Lee, Sung-Eun HSIN-AN HOU Sato, Toshiaki Qin, Albert Urbanski, Raymond Shih, Weichung Zagrijtschuk, Oleh Zimmerman, Craig Verstovsek, Srdan |
關鍵字: | MPN; P1101; Trial-in-Progress; anagrelide; essential thrombocythemia; myeloproliferative neoplasm; ropeginterferon alfa-2b-njft | 公開日期: | 十月-2022 | 卷: | 22 Suppl 2 | 起(迄)頁: | S342 | 來源出版物: | Clinical lymphoma, myeloma & leukemia | 摘要: | Low-dose aspirin with hydroxyurea (HU) is first-line therapy in high-risk essential thrombocythemia (ET). However, many patients become HU-intolerant or -resistant. Anagrelide (ANA) and peginterferon alfa-2a are second-line options for high-risk ET patients. |
URI: | https://pubmed.ncbi.nlm.nih.gov/36164019/ https://www.scopus.com/inward/record.uri?eid=2-s2.0-85138182278&doi=10.1016%2fS2152-2650%2822%2901468-9&partnerID=40&md5=df1eb1e80662f6697ae5c921e8cd48a7 https://scholars.lib.ntu.edu.tw/handle/123456789/635379 |
ISSN: | 21522650 | DOI: | 10.1016/S2152-2650(22)01468-9 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。